XHKG9996
Market cap335mUSD
Jan 07, Last price
3.99HKD
1D
1.27%
1Q
4.18%
IPO
-85.52%
Name
Peijia Medical Ltd
Chart & Performance
Profile
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 441,126 75.86% | 250,833 83.71% | ||||
Cost of revenue | 875,794 | 823,345 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (434,668) | (572,512) | ||||
NOPBT Margin | ||||||
Operating Taxes | 1,052 | 9,574 | ||||
Tax Rate | ||||||
NOPAT | (435,720) | (582,086) | ||||
Net income | (392,525) -3.75% | (407,809) -28.98% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 4,055 | (8,258) | ||||
BB yield | ||||||
Debt | ||||||
Debt current | 16,414 | 58,953 | ||||
Long-term debt | 208,434 | 75,814 | ||||
Deferred revenue | 1,720 | |||||
Other long-term liabilities | 38,914 | (22,040) | ||||
Net debt | (1,111,190) | (2,023,816) | ||||
Cash flow | ||||||
Cash from operating activities | (583,485) | (376,196) | ||||
CAPEX | (175,624) | (130,412) | ||||
Cash from investing activities | (386,291) | (463,277) | ||||
Cash from financing activities | 85,108 | 117,438 | ||||
FCF | (723,042) | (720,145) | ||||
Balance | ||||||
Cash | 942,925 | 1,743,097 | ||||
Long term investments | 393,113 | 415,486 | ||||
Excess cash | 1,313,982 | 2,146,041 | ||||
Stockholders' equity | (4,104,885) | (3,648,716) | ||||
Invested Capital | 6,639,014 | 6,410,535 | ||||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 679,275 | 673,160 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (391,866) | (538,529) | ||||
EV/EBITDA | ||||||
Interest | 178 | 2,316 | ||||
Interest/NOPBT |